Near-infrared fluorescence imaging of lymph nodes using a new enzyme sensing activatable macromolecular optical probe

The aim of this study was to validate the use of near infrared fluorescence imaging (NIRF) using enzyme-sensitive optical probes for lymph node detection. An optical contrast probe that is activated by cystein proteases, such as cathepsin B, was used to visualize lymph nodes by NIRF reflectance imaging. In order to quantitate the uptake of the optical probe in lymphatic tissue, the biodistribution was assessed using the Indium-111 labeled optical probe. Sixteen Balb-c mice were injected either intravenously (i.v.) or subcutaneously (s.c.) with the NIRF-probe (2 μmol cyanine (Cy)/animal; i.v., n=10; s.c., n=6) and imaged 24 h after injection. Signal intensities and target-to-background ratios of various lymph nodes were measured by manual regions of interest (ROIs). Additional signal intensity measurements were performed of excised lymph nodes (n=21) from i.v. injected mice (24 h after injection) and compared with excised lymph nodes (n=8) of non-injected mice. The probe employed in this study was lymphotropic with approximately 3–4% accumulation in lymph nodes (3.4±0.8% ID/g). Measurements of the excised lymph nodes (after i.v. injection) confirmed a significant increase in lymph node fluorescence signal from baseline 26±7.6 arbitary units (AU) to 146±10.9 AU (p<0.0001). A significant increase in lymph node fluorescence signal was also seen in vivo throughout the body after i.v. injection (96±7.8 AU) and/or regionally after s.c. injection (141±11.5 AU) in comparison with baseline autofluorescence (26±7.6 AU). Target-to-background ratio was significantly higher after s.c. injection (6.6%±0.81) compared with i.v. injection (4.8±0.67%). Detection and visualization of lymph nodes is feasible by NIRF imaging using a cystein-protease sensitive optical probe.

[1]  L. Skoog,et al.  Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Stockholm Breast Cancer Study Group. , 1992, Acta oncologica.

[2]  L V Wang Optical tomography for biomedical applications. , 1998, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.

[3]  J. Schneider-Mergener,et al.  Cyanine Dye Labeled Vasoactive Intestinal Peptide and Somatostatin Analog for Optical Detection of Gastroenteropancreatic Tumors , 2000, Annals of the New York Academy of Sciences.

[4]  Hong Wang,et al.  Investigation of Mechanisms Influencing the Accumulation of Ultrasmall Superparamagnetic Iron Oxide Particles in Lymph Nodes , 1995, Investigative radiology.

[5]  S. Achilefu,et al.  Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. , 2000, Investigative radiology.

[6]  R. Weissleder,et al.  Long-circulating blood pool imaging agents , 1995 .

[7]  D. Steiner,et al.  The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumors. , 1991, Biomedica biochimica acta.

[8]  R. Weissleder Molecular imaging: exploring the next frontier. , 1999, Radiology.

[9]  Ralph Weissleder,et al.  In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.

[10]  M. Fan,et al.  Lymph node micrometastases from breast carcinoma , 1997, Cancer.

[11]  R Weissleder,et al.  MR lymphography: study of a high-efficiency lymphotrophic agent. , 1994, Radiology.

[12]  V. Ntziachristos,et al.  Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Weissleder,et al.  A long-circulating co-polymer in "passive targeting" to solid tumors. , 1997, Journal of drug targeting.

[14]  M D Blaufox,et al.  PET imaging in oncology. , 2000, Seminars in nuclear medicine.

[15]  Robert E. Lenkinski,et al.  In vivo near-infrared fluorescence imaging of osteoblastic activity , 2001, Nature Biotechnology.

[16]  H. G. Rylander,et al.  Use of an agent to reduce scattering in skin , 1999, Lasers in surgery and medicine.

[17]  O. Clément,et al.  Distribution of iron oxide nanoparticles in rat lymph nodes studied using electron energy loss spectroscopy (EELS) and electron spectroscopic imaging (ESI) , 2000, Journal of magnetic resonance imaging : JMRI.

[18]  R. Weissleder,et al.  Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging , 2002, European Radiology.

[19]  V. Ntziachristos,et al.  Fortschritte in der optischen Bildgebung , 2001, Der Radiologe.

[20]  R. Weissleder,et al.  [Progress in optical imaging]. , 2001, Der Radiologe.

[21]  W. Semmler,et al.  Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands , 2001, Nature Biotechnology.

[22]  D. Eshima,et al.  Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. , 1997, Seminars in nuclear medicine.

[23]  G. Frija,et al.  MR lymphography using iron oxide nanoparticles in rats: Pharmacokinetics in the lymphatic system after intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.

[24]  G. Frija,et al.  Experimental investigation of the delivery pathway of ultrasmall superparamagnetic iron oxide to lymph nodes. , 1996, Academic radiology.

[25]  R. Weissleder,et al.  Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages , 1997, Journal of magnetic resonance imaging : JMRI.

[26]  K Kubota,et al.  Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  D Jacqmin,et al.  Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. , 1998, Radiology.

[28]  Robert G. Moore,et al.  Initial clinical experience , 1997 .

[29]  R Weissleder,et al.  In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. , 2000, Cancer research.

[30]  Wolfhard Semmler,et al.  Macromolecular Contrast Agents for Optical Imaging of Tumors: Comparison of Indotricarbocyanine-labeled Human Serum Albumin and Transferrin¶ , 2000, Photochemistry and photobiology.

[31]  R Weissleder,et al.  Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. , 1999, Bioconjugate chemistry.

[32]  R. Weissleder,et al.  Optical-based molecular imaging: contrast agents and potential medical applications , 2003, European Radiology.

[33]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[34]  L. Svaasand,et al.  Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. , 2000, Neoplasia.

[35]  A. Howie,et al.  The distribution of cathespin b in human tissues , 1985, The Journal of pathology.

[36]  A. Recht,et al.  Axillary lymph nodes and breast cancer. A review , 1995, Cancer.

[37]  S. Achilefu,et al.  Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. , 2001, Journal of biomedical optics.

[38]  W Semmler,et al.  Synthesis, characterization, and biological properties of cyanine-labeled somatostatin analogues as receptor-targeted fluorescent probes. , 2001, Bioconjugate chemistry.

[39]  V. Ntziachristos,et al.  Hydrophilic Cyanine Dyes as Contrast Agents for Near-infrared Tumor Imaging: Synthesis, Photophysical Properties and Spectroscopic In vivo Characterization¶ , 2000, Photochemistry and photobiology.

[40]  R Weissleder,et al.  Near-infrared optical imaging of protease activity for tumor detection. , 1999, Radiology.